Lineage Cell Therapeutics, Inc. (LCTX)

↓ Download CSV

CIK 0000876343 · NYSE · Biological Products, (No Diagnostic Substances)

  • Sector Manufacturing
  • Incorporated CA
  • Fiscal year ends Dec 31

In fiscal 2025, Lineage Cell Therapeutics, Inc. reported revenue of $14.56M, up 53.2% from the prior year. The company ran a net loss, with a net margin of -436.5%. It held $112.58M in total assets against $69.24M in total liabilities.

Key ratios (FY2025)

-251.6%
Operating margin
-436.5%
Net margin
-146.6%
Return on equity
+53.2%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$14.56M$9.50M$8.95M$14.70M$4.34M$1.83M
Cost of Revenue$334.0K$671.0K$728.0K$1.43M$385.0K$412.0K$302.0K$168.0K$358.0K
Gross Profit$8.27M$13.97M$2.92M$1.44M$3.10M$4.69M$3.29M$5.57M
Operating Income-$36.62M-$21.48M-$24.73M-$22.52M-$49.21M-$26.45M-$38.88M-$41.80M-$38.90M-$58.97M
Net Income-$63.53M-$18.61M-$21.49M-$26.27M-$43.02M-$20.65M-$11.71M-$45.99M-$19.98M$33.57M
EPS (Diluted)$-0.28$-0.09$-0.12$-0.15$-0.26$-0.17$0.35
Total Assets$112.58M$113.22M$101.02M$123.66M$174.54M$107.95M$125.48M$101.66M$173.24M$142.57M
Total Liabilities$69.24M$36.21M$39.00M$51.73M$83.65M$12.82M$14.23M$9.41M$8.98M$12.06M
Shareholders' Equity$43.35M$77.01M$62.02M$71.94M$90.90M$95.13M$111.25M$92.25M$164.26M$130.51M
Cash & Equivalents$40.79M$45.79M$35.44M$11.36M$55.74M$32.59M$9.50M$23.59M$36.84M$22.09M
Operating Cash Flow-$18.92M-$23.09M-$28.57M$1.06M-$23.56M-$19.75M-$31.95M-$30.88M-$30.52M-$42.33M
Capital Expenditures$522.0K$565.0K$674.0K$413.0K$340.0K$64.0K$440.0K$556.0K$1.33M$2.25M
Shares Outstanding243.12M220.42M174.99M170.09M169.48M153.10M149.80M127.14M126.87M102.78M